SPI Reports 83% Increase Over Last Year’s Earnings
SPI Pharmaceuticals of Costa Mesa posted fiscal third-quarter earnings of $1.6 million, an 83% rise from the $857,000 reported in the same period last year. Revenues for the quarter ended Aug. 31 increased 79% to $20.4 million from $11.4 million.
Earnings for the nine-month period increased 42% to $7.4 million, from the $5.2 million posted in the same period last year. Revenues were $52.5%, up 34% from $39.2 million.
SPI stock closed Thursday at $14.50 per share in over-the-counter trading, up $1.50 from Wednesday’s close. SPI manufactures and distributes pharmaceutical products and related services, primarily in the North America and Europe. It is a subsidiary of ICN Pharmaceuticals, which is expected to release its earnings in upcoming weeks. SPI officials were not available for comment.
Start your day right
Sign up for Essential California for news, features and recommendations from the L.A. Times and beyond in your inbox six days a week.
You may occasionally receive promotional content from the Los Angeles Times.
